INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4565 participants.
Also called NCT02832544
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 4,565 participants
- Registry
-
NCT02832544
-
- Other papers using this trial's data
- Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Botswana, Brazil, Cameroon, China, Egypt, Ethiopia, India, Kazakhstan, Kenya, Kyrgyzstan, Malawi, Mexico, Mozambique, Nepal, Nigeria, Pakistan, Paraguay, Philippines, Rwanda, South Africa, Sudan, Tanzania, Uganda, Zambia, Zimbabwe
- Registry status
- Completed
Technical summary
Registry record NCT02832544. Randomized; no masking; primary purpose prevention. Start 2016-08-22 (actual); primary completion 2022-08-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
- Acronym
- INVICTUS-VKA
- Condition
- Rheumatic Heart Disease
- Intervention (Drug)
- Rivaroxaban (20 mg)
- Intervention (Drug)
- Vitamin K antagonists (VKA)
- Lead sponsor
- Population Health Research Institute
- Collaborator
- University of Cape Town
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02832544- Content hash
f8ba9b73873e5396d95eb94736bd7b62d7bfe9d8a8f3d37501a6ee23f5baea84